nodes	percent_of_prediction	percent_of_DWPC	metapath
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA6—nicotine dependence	0.0464	0.0953	CbGpPWpGaD
Dextroamphetamine—Dysphoria—Varenicline—nicotine dependence	0.0434	0.0846	CcSEcCtD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA5—nicotine dependence	0.0299	0.0614	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA3—nicotine dependence	0.0244	0.0501	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNB2—nicotine dependence	0.0215	0.0441	CbGpPWpGaD
Dextroamphetamine—Accidental injury—Varenicline—nicotine dependence	0.0212	0.0413	CcSEcCtD
Dextroamphetamine—Viral infection—Varenicline—nicotine dependence	0.0208	0.0405	CcSEcCtD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—CHRNA4—nicotine dependence	0.0195	0.04	CbGpPWpGaD
Dextroamphetamine—TAAR1—Amine ligand-binding receptors—DRD2—nicotine dependence	0.0191	0.0392	CbGpPWpGaD
Dextroamphetamine—Blood pressure increased—Varenicline—nicotine dependence	0.0188	0.0366	CcSEcCtD
Dextroamphetamine—Euphoric mood—Varenicline—nicotine dependence	0.0161	0.0314	CcSEcCtD
Dextroamphetamine—SLC18A2—Nicotine Activity on Dopaminergic Neurons—DRD2—nicotine dependence	0.0159	0.0326	CbGpPWpGaD
Dextroamphetamine—CYP2D6—CYP2E1 reactions—CYP2A7—nicotine dependence	0.0157	0.0323	CbGpPWpGaD
Dextroamphetamine—Injury—Varenicline—nicotine dependence	0.0148	0.0289	CcSEcCtD
Dextroamphetamine—Libido decreased—Varenicline—nicotine dependence	0.0147	0.0286	CcSEcCtD
Dextroamphetamine—Cerebrovascular accident—Varenicline—nicotine dependence	0.0139	0.0271	CcSEcCtD
Dextroamphetamine—Disturbance in sexual arousal—Varenicline—nicotine dependence	0.0135	0.0263	CcSEcCtD
Dextroamphetamine—Affect lability—Varenicline—nicotine dependence	0.0134	0.0261	CcSEcCtD
Dextroamphetamine—Psychotic disorder—Varenicline—nicotine dependence	0.0133	0.0259	CcSEcCtD
Dextroamphetamine—Irritability—Varenicline—nicotine dependence	0.013	0.0253	CcSEcCtD
Dextroamphetamine—Mood swings—Varenicline—nicotine dependence	0.0129	0.0251	CcSEcCtD
Dextroamphetamine—Abdominal pain upper—Varenicline—nicotine dependence	0.0124	0.0242	CcSEcCtD
Dextroamphetamine—CYP2D6—Fatty acids—CYP2A7—nicotine dependence	0.0123	0.0252	CbGpPWpGaD
Dextroamphetamine—Erectile dysfunction—Varenicline—nicotine dependence	0.0108	0.0211	CcSEcCtD
Dextroamphetamine—Photosensitivity reaction—Varenicline—nicotine dependence	0.0107	0.0209	CcSEcCtD
Dextroamphetamine—Depression—Varenicline—nicotine dependence	0.0105	0.0204	CcSEcCtD
Dextroamphetamine—Stevens-Johnson syndrome—Varenicline—nicotine dependence	0.0104	0.0203	CcSEcCtD
Dextroamphetamine—Acute coronary syndrome—Varenicline—nicotine dependence	0.0103	0.0202	CcSEcCtD
Dextroamphetamine—Myocardial infarction—Varenicline—nicotine dependence	0.0103	0.0201	CcSEcCtD
Dextroamphetamine—CYP2D6—Xenobiotics—CYP2A7—nicotine dependence	0.00974	0.02	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—TAS2R16—nicotine dependence	0.00937	0.0192	CbGpPWpGaD
Dextroamphetamine—Erythema multiforme—Varenicline—nicotine dependence	0.00891	0.0174	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00806	0.0166	CbGpPWpGaD
Dextroamphetamine—Tremor—Varenicline—nicotine dependence	0.00769	0.015	CcSEcCtD
Dextroamphetamine—ADRA1B—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.00766	0.0157	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00765	0.0157	CbGpPWpGaD
Dextroamphetamine—Agitation—Varenicline—nicotine dependence	0.00754	0.0147	CcSEcCtD
Dextroamphetamine—Angioedema—Varenicline—nicotine dependence	0.0075	0.0146	CcSEcCtD
Dextroamphetamine—Palpitations—Varenicline—nicotine dependence	0.00725	0.0141	CcSEcCtD
Dextroamphetamine—Convulsion—Varenicline—nicotine dependence	0.00711	0.0139	CcSEcCtD
Dextroamphetamine—Hypertension—Varenicline—nicotine dependence	0.00708	0.0138	CcSEcCtD
Dextroamphetamine—Chest pain—Varenicline—nicotine dependence	0.00699	0.0136	CcSEcCtD
Dextroamphetamine—Anxiety—Varenicline—nicotine dependence	0.00696	0.0136	CcSEcCtD
Dextroamphetamine—Dry mouth—Varenicline—nicotine dependence	0.00683	0.0133	CcSEcCtD
Dextroamphetamine—ADRA1A—G alpha (12/13) signalling events—FGD1—nicotine dependence	0.0068	0.014	CbGpPWpGaD
Dextroamphetamine—Infection—Varenicline—nicotine dependence	0.00665	0.013	CcSEcCtD
Dextroamphetamine—Tachycardia—Varenicline—nicotine dependence	0.00654	0.0127	CcSEcCtD
Dextroamphetamine—Hyperhidrosis—Varenicline—nicotine dependence	0.00647	0.0126	CcSEcCtD
Dextroamphetamine—Anorexia—Varenicline—nicotine dependence	0.00638	0.0124	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNB3—nicotine dependence	0.00618	0.0127	CbGpPWpGaD
Dextroamphetamine—Insomnia—Varenicline—nicotine dependence	0.00606	0.0118	CcSEcCtD
Dextroamphetamine—Dyspnoea—Varenicline—nicotine dependence	0.00597	0.0116	CcSEcCtD
Dextroamphetamine—Somnolence—Varenicline—nicotine dependence	0.00595	0.0116	CcSEcCtD
Dextroamphetamine—Dyspepsia—Varenicline—nicotine dependence	0.00589	0.0115	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA6—nicotine dependence	0.00586	0.012	CbGpPWpGaD
Dextroamphetamine—Decreased appetite—Varenicline—nicotine dependence	0.00582	0.0113	CcSEcCtD
Dextroamphetamine—Gastrointestinal disorder—Varenicline—nicotine dependence	0.00578	0.0113	CcSEcCtD
Dextroamphetamine—Fatigue—Varenicline—nicotine dependence	0.00577	0.0112	CcSEcCtD
Dextroamphetamine—ADRA1B—Monoamine GPCRs—DRD2—nicotine dependence	0.00574	0.0118	CbGpPWpGaD
Dextroamphetamine—Constipation—Varenicline—nicotine dependence	0.00573	0.0112	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00553	0.0114	CbGpPWpGaD
Dextroamphetamine—Gastrointestinal pain—Varenicline—nicotine dependence	0.00548	0.0107	CcSEcCtD
Dextroamphetamine—Urticaria—Varenicline—nicotine dependence	0.00532	0.0104	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.0053	0.0109	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00529	0.0109	CbGpPWpGaD
Dextroamphetamine—Body temperature increased—Varenicline—nicotine dependence	0.00529	0.0103	CcSEcCtD
Dextroamphetamine—Abdominal pain—Varenicline—nicotine dependence	0.00529	0.0103	CcSEcCtD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00519	0.0107	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Monoamine GPCRs—DRD2—nicotine dependence	0.0051	0.0105	CbGpPWpGaD
Dextroamphetamine—Hypersensitivity—Varenicline—nicotine dependence	0.00493	0.00961	CcSEcCtD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00493	0.0101	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00482	0.00991	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—TAS2R16—nicotine dependence	0.00481	0.00988	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB3—nicotine dependence	0.00481	0.00988	CbGpPWpGaD
Dextroamphetamine—Asthenia—Varenicline—nicotine dependence	0.0048	0.00936	CcSEcCtD
Dextroamphetamine—Diarrhoea—Varenicline—nicotine dependence	0.00458	0.00893	CcSEcCtD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA6—nicotine dependence	0.00456	0.00936	CbGpPWpGaD
Dextroamphetamine—Dizziness—Varenicline—nicotine dependence	0.00443	0.00863	CcSEcCtD
Dextroamphetamine—ADRA1A—Amine ligand-binding receptors—DRD2—nicotine dependence	0.00428	0.0088	CbGpPWpGaD
Dextroamphetamine—Vomiting—Varenicline—nicotine dependence	0.00426	0.0083	CcSEcCtD
Dextroamphetamine—SLC18A2—Neuronal System—GABRA4—nicotine dependence	0.00423	0.0087	CbGpPWpGaD
Dextroamphetamine—Rash—Varenicline—nicotine dependence	0.00422	0.00823	CcSEcCtD
Dextroamphetamine—Dermatitis—Varenicline—nicotine dependence	0.00422	0.00822	CcSEcCtD
Dextroamphetamine—Headache—Varenicline—nicotine dependence	0.00419	0.00817	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR downstream signaling—FGD1—nicotine dependence	0.00415	0.00854	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNB4—nicotine dependence	0.00406	0.00834	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A7—nicotine dependence	0.00404	0.00831	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00402	0.00825	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Oxidation by Cytochrome P450—CYP2A7—nicotine dependence	0.00399	0.0082	CbGpPWpGaD
Dextroamphetamine—Nausea—Varenicline—nicotine dependence	0.00398	0.00775	CcSEcCtD
Dextroamphetamine—TAAR1—GPCR ligand binding—OPRM1—nicotine dependence	0.00395	0.00811	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA5—nicotine dependence	0.00377	0.00775	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—FGD1—nicotine dependence	0.00377	0.00775	CbGpPWpGaD
Dextroamphetamine—TAAR1—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.00375	0.0077	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNB3—nicotine dependence	0.00368	0.00757	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00354	0.00726	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA6—nicotine dependence	0.00349	0.00717	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—GABRA4—nicotine dependence	0.00329	0.00677	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A7—nicotine dependence	0.00328	0.00673	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00321	0.0066	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB4—nicotine dependence	0.00316	0.00649	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA3—nicotine dependence	0.00308	0.00632	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA5—nicotine dependence	0.00294	0.00603	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR ligand binding—DRD2—nicotine dependence	0.00286	0.00587	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—TAS2R16—nicotine dependence	0.00284	0.00584	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNB2—nicotine dependence	0.00271	0.00557	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—GABRA4—nicotine dependence	0.00252	0.00519	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Neuronal System—CHRNA4—nicotine dependence	0.00246	0.00505	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNB4—nicotine dependence	0.00242	0.00497	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA3—nicotine dependence	0.00239	0.00492	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—TAS2R16—nicotine dependence	0.00237	0.00487	CbGpPWpGaD
Dextroamphetamine—SLC18A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00228	0.00468	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA5—nicotine dependence	0.00225	0.00462	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—OPRM1—nicotine dependence	0.00223	0.00459	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—FGD1—nicotine dependence	0.00223	0.00458	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNB2—nicotine dependence	0.00211	0.00433	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—TAS2R16—nicotine dependence	0.00211	0.00433	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—OPRM1—nicotine dependence	0.00203	0.00416	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—AKR1B10—nicotine dependence	0.00197	0.00404	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmission across Chemical Synapses—CHRNA4—nicotine dependence	0.00191	0.00393	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—AKR1B10—nicotine dependence	0.00185	0.0038	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA3—nicotine dependence	0.00183	0.00377	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Biological oxidations—CYP2A7—nicotine dependence	0.00174	0.00358	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metapathway biotransformation—CYP2A7—nicotine dependence	0.00172	0.00353	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNB2—nicotine dependence	0.00161	0.00332	CbGpPWpGaD
Dextroamphetamine—TAAR1—GPCR downstream signaling—DRD2—nicotine dependence	0.00161	0.00332	CbGpPWpGaD
Dextroamphetamine—SLC6A2—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00153	0.00315	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00153	0.00315	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Neuronal System—CHRNA4—nicotine dependence	0.00147	0.00301	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling by GPCR—DRD2—nicotine dependence	0.00147	0.00301	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—WASF2—nicotine dependence	0.00139	0.00285	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—OPRM1—nicotine dependence	0.00136	0.00279	CbGpPWpGaD
Dextroamphetamine—SLC6A3—Transmembrane transport of small molecules—GABRA4—nicotine dependence	0.00136	0.00279	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00134	0.00275	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—WASF1—nicotine dependence	0.00133	0.00273	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00131	0.0027	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—TAS2R16—nicotine dependence	0.00122	0.0025	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—OPRM1—nicotine dependence	0.0012	0.00246	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—TAS2R16—nicotine dependence	0.00119	0.00244	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—OPRM1—nicotine dependence	0.00117	0.00239	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.00111	0.00227	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—TAS2R16—nicotine dependence	0.00108	0.00222	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—FGD1—nicotine dependence	0.00105	0.00216	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—OPRM1—nicotine dependence	0.000999	0.00205	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCRs, Class A Rhodopsin-like—DRD2—nicotine dependence	0.000983	0.00202	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—FGD1—nicotine dependence	0.000954	0.00196	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000949	0.00195	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—FGD1—nicotine dependence	0.000934	0.00192	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—OPRM1—nicotine dependence	0.000887	0.00182	CbGpPWpGaD
Dextroamphetamine—TAAR1—Signaling Pathways—DRD2—nicotine dependence	0.000866	0.00178	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—FGD1—nicotine dependence	0.000848	0.00174	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Class A/1 (Rhodopsin-like receptors)—DRD2—nicotine dependence	0.000843	0.00173	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR ligand binding—DRD2—nicotine dependence	0.000722	0.00148	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—TAS2R16—nicotine dependence	0.000719	0.00148	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR ligand binding—DRD2—nicotine dependence	0.000642	0.00132	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—TAS2R16—nicotine dependence	0.000638	0.00131	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—OPRM1—nicotine dependence	0.000565	0.00116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—FGD1—nicotine dependence	0.000564	0.00116	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—OPRM1—nicotine dependence	0.000513	0.00105	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—OPRM1—nicotine dependence	0.000502	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—FGD1—nicotine dependence	0.000501	0.00103	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—AKR1B10—nicotine dependence	0.000498	0.00102	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—OPRM1—nicotine dependence	0.000455	0.000936	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—AKR1B10—nicotine dependence	0.000442	0.000909	CbGpPWpGaD
Dextroamphetamine—ADRA1B—GPCR downstream signaling—DRD2—nicotine dependence	0.000408	0.000839	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling by GPCR—DRD2—nicotine dependence	0.000371	0.000762	CbGpPWpGaD
Dextroamphetamine—ADRA1A—GPCR downstream signaling—DRD2—nicotine dependence	0.000363	0.000745	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—WASF2—nicotine dependence	0.000351	0.000721	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—WASF1—nicotine dependence	0.000336	0.000691	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling by GPCR—DRD2—nicotine dependence	0.000329	0.000676	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—WASF2—nicotine dependence	0.000312	0.00064	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—OPRM1—nicotine dependence	0.000303	0.000622	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—WASF1—nicotine dependence	0.000299	0.000614	CbGpPWpGaD
Dextroamphetamine—CYP2D6—Metabolism—CYP2A7—nicotine dependence	0.000298	0.000612	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—OPRM1—nicotine dependence	0.000269	0.000553	CbGpPWpGaD
Dextroamphetamine—ADRA1B—Signaling Pathways—DRD2—nicotine dependence	0.000219	0.00045	CbGpPWpGaD
Dextroamphetamine—ADRA1A—Signaling Pathways—DRD2—nicotine dependence	0.000195	0.0004	CbGpPWpGaD
